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1. Abstract 29 
Objectives 30 
To identify subgroups for whom supported self-help preventive cognitive therapy (S-PCT) is more 31 
(cost)effective than treatment as usual (TAU) in preventing relapse and recurrence of major 32 
depression. 33 
Methods 34 
We conducted a randomized controlled trial in which 248 remitted, recurrently depressed 35 
participants were randomized to S-PCT (n=124) or TAU (n=124). Clinical outcome was relapse or 36 
recurrence of major depressive disorder (SCID-I). We tested the potential moderating effects on 37 
relapse or recurrence of age, gender, education level, residual depressive symptoms, number of 38 
previous episodes, age of onset, antidepressant medication, somatization, and self-efficacy with 39 
logistic regression analyses adjusted for baseline values of depressive symptoms. We examined 40 
moderating effects on costs using linear regression analyses adjusted for baseline costs. A stratified 41 
cost-effectiveness analysis was performed to tease out differences in cost-effectiveness between 42 
subgroups. 43 
Results 44 
We found no moderating effect on relapse or recurrence for any of the potential moderators. For 45 
costs, the number of previous depressive episodes was identified as a moderator. At a willingness-to-46 
pay of 16,000€, the probability that S-PCT was cost-effective compared to TAU was 95% for 47 
participants with 2-3 previous episodes and 11% for participants with ≥4 episodes. 48 
Conclusions 49 
S-PCT was effective in preventing relapse or recurrence of depressive disorders in a broad range of 50 
participants, but is more likely to be cost-effective in participants with 2-3 episodes than with ≥4 51 
episodes. This indicates that S-PCT can best be offered to participants with fewer previous depressive 52 
episodes.  53 
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2. Introduction 54 
Major depressive disorder is a leading cause of disability worldwide [1] and is associated with 55 
substantial societal costs as a result of increased health care utilization and productivity losses [2-3]. 56 
Its high disease burden is largely due to its recurrent nature. For instance, Mueller et al. (1999) found 57 
that 85% of recovered persons reported a recurrence during 15 years follow-up and that the risk of 58 
recurrence was increased by 18 % with each additional episode [4].  59 
Interventions aimed at the prevention of relapse or recurrence might reduce the burden of 60 
depressive disorders by approximately 50% [5]. Both antidepressants and several psychological 61 
treatments, such as Preventive Cognitive Therapy (PCT) and mindfulness-based cognitive therapy 62 
(MBCT), are effective in the prevention of relapse or recurrences of depressive disorders [6-8]. 63 
However, people may find long-term use of antidepressants unattractive and non-adherence to 64 
continuation and maintenance of antidepressants for recurrent depression is high [9-10]. As for 65 
psychological treatment, psychologists may be less available in the primary care setting or people do 66 
not want to engage in therapeutic sessions when they are not experiencing many symptoms at that 67 
moment [9]. Therefore, offering a preventive psychological treatment, such as Preventive Cognitive 68 
Therapy (PCT) in a supported self-help format would be a major step forwards. PCT is an adapted 69 
version of Cognitive Therapy for acute depression [11] and aims to prevent relapse and recurrence by 70 
focusing on changing negative thoughts and dysfunctional attitudes. The Parade study examined 71 
whether PCT in a supported self-help format (S-PCT) was cost-effective in comparison with treatment 72 
as usual (TAU) to prevent relapse or recurrence of depressive disorders [12]. The study showed that 73 
S-PCT significantly reduced relapse and recurrence rates by 14% after twelve months and that 74 
€13,515 should be invested to prevent one relapse or recurrence in the S-PCT group in comparison 75 
with the TAU group [13-14].  76 
It is, however, not yet clear whether subgroups can be identified that respond particularly well to 77 
supported self-help for recurrent depression. Distinguishing characteristics of persons that benefited 78 
most could help target the use of this supported self-help PCT. In this study we examined for which 79 
subgroups of remitted, recurrently depressed persons S-PCT was a (cost)effective addition as 80 
compared to treatment as usual (TAU) in preventing relapse and recurrence of depressive disorders.  81 
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3. Materials and methods 82 
Design 83 
We performed a pragmatic randomized controlled trial (n = 248) with two parallel groups: S-PCT plus 84 
TAU (n = 124) compared to TAU alone (n = 124). Participants with at least two episodes of depression 85 
who were at that time remitted were recruited in primary care practices and specialized mental 86 
health care institutions in the Netherlands and were observed for twelve months. The design and 87 
(cost)effectiveness results of this study have been described elsewhere [12-14].  88 
Participants 89 
Participants were eligible for participation if they: 1) were more than 18 years old, 2) had 90 
experienced at least two previous depressive episodes, and 3) were remitted according to a 91 
Structured Clinical Interview for DSM-IV (SCID-I) [15] with a trained interviewer. Their most recent, 92 
remitted depressive episode should have been longer than eight weeks, but not longer than five 93 
years ago. Having residual, subclinical depressive symptoms was not an exclusion criterion. Exclusion 94 
criteria were severe cognitive impairment; history of mania, hypomania or psychosis; current alcohol 95 
or drug-related abuse or dependence as the principal diagnosis; insufficient mastery of the Dutch 96 
language. Eligibility criteria were checked in patient medical records and during the SCID-I interview 97 
which took place by phone. 98 
Intervention 99 
S-PCT is  a supported self-help treatment based on PCT [16-17], an adapted version of cognitive 100 
therapy for acute depression [11]. PCT aims to help remitted participants with a history of depression 101 
in preventing relapse and recurrence. Participants have to work through a self-help book with 102 
background literature and assignments, consisting of eight weekly modules. S-PCT starts with the 103 
identification of negative thoughts and dysfunctional attitudes. Next, the focus of S-PCT is directed 104 
on changing these attitudes by using various cognitive techniques such as identification of positive 105 
attitudes and enhancing specific memories of positive experiences. In the last modules of S-PCT, the 106 
participant formulates specific relapse and recurrence prevention strategies in a personal prevention 107 
plan. Counselors, i.e. certified mental health nurses and psychologists, supported the participants 108 
during weekly telephone calls (max. 15 minutes). The counselor aimed to evaluate progress and 109 
understanding and not to engage actively in a therapeutic relationship. 110 
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Treatment as usual 111 
In both conditions, TAU included routine treatment according to the Dutch clinical guidelines [18-19]. 112 
These guidelines recommend continuation of antidepressant medication, preventive psychological 113 
treatment, or both, depending on the level of dysfunctioning and distress, psychiatric or somatic co-114 
morbidity, and preferences of the participant. In both groups, there were no restrictions on TAU and 115 
TAU could also consist of no treatment. 116 
Recruitment of participants and treatment allocation 117 
Medical records of 22 primary care practices and four specialized mental health care institutions 118 
were screened for possibly eligible participants. This led to the identification of 5.489 persons, who 119 
received a short information letter and a screening questionnaire. Responding persons who were 120 
eligible according to the global screening questionnaire received detailed study information and an 121 
informed consent form. Once participants had provided informed consent, they received the SCID-I 122 
interview over the phone to assess eligibility criteria in detail. If participants met the criteria, they 123 
were randomly assigned to S-PCT plus TAU (n = 124) or TAU alone (n = 124) using a blockwise 124 
randomization scheme. Randomization was stratified according to the number of previous episodes 125 
(two or three previous episodes versus four or more episodes).  126 
Measurements 127 
Clinical outcome 128 
Relapse or recurrence, our primary outcome, was defined as meeting DSM-IV criteria for a major 129 
depressive episode [20], as measured by the SCID-I interview at six and twelve months follow-up.  130 
Cost outcomes 131 
Costs were assessed from a societal perspective, including costs of the S-PCT intervention (bottom-132 
up approach), health care utilization, and productivity losses (human capital approach). Health care 133 
utilization and productivity costs were measured using the Trimbos and iMTA self-report 134 
questionnaire for Costs associated with Psychiatric Illnesses (TiC-P) [21] at three, six, nine and twelve 135 
months of follow-up. Valuation of health care utilization and lost productivity was done according to 136 
Dutch guidelines [22].  137 
Effect moderators 138 
We hypothesized that participants at higher risk for relapse or recurrence would benefit the most 139 
from PCT.  Several risk factors for relapse or recurrence of depression may predict treatment 140 
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response, particularly the number of depressive episodes and residual depressive symptoms [23-25]. 141 
We included these factors as effect moderators. 142 
Sociodemographic characteristics 143 
Age, gender, and education level (low versus high education) were assessed by means of a self-report 144 
questionnaire at baseline. We expected that a higher education level is associated with a better 145 
treatment response [26-27]. High education level was defined as a bachelor’s or master’s degree, 146 
whereas low education was defined as any education below a bachelor’s or master’s degree. 147 
Clinical and psychosocial characteristics 148 
The number of previous depressive episodes and the level of initial residual depressive symptoms are 149 
strongly associated with an increased risk of relapse or recurrence [24, 28]. The level of residual 150 
depressive symptoms was measured with the QIDS-sr [29]. The number of previous depressive 151 
episodes was assessed in a self-report questionnaire and dichotomized to two or three episodes 152 
versus four or more episodes. 153 
Second, a younger age of onset of the first episode may be associated with a poorer prognosis 154 
regarding the course of depression but the evidence is still inconclusive (24, 30]. Due to its putative 155 
association with relapse or recurrence of depressive disorders, age of onset (self-report) was 156 
considered as a potential effect moderator.  157 
Third, the use of antidepressant medication may influence treatment response positively and was 158 
measured at baseline (TiC-P, dichotomous), over the past three months [31]. 159 
Fourth, somatization increases the risk of recurrence [32] and negatively affects the prognosis of 160 
depressive disorders [33]. Somatization can be defined as “the tendency to experience and 161 
communicate somatic distress and symptoms unaccounted for by pathological findings, to attribute 162 
them to physical illness, and to seek medical help for them” [34]. We measured somatization at 163 
baseline by the Four-Dimensional Symptom Questionnaire (4DSQ) somatization scale [35]. The 4DSQ 164 
operationalizes somatization as a high number and frequency of physical symptoms. Experiencing 165 
some physical symptoms unaccounted for by pathological findings is a common phenomenon, while 166 
experiencing multiple (unexplained) physical symptoms from different organ systems implies 167 
probably somatization [35-36]. The 4DSQ somatization scale consists of 16 symptoms (e.g. during the 168 
past week did you suffer from dizziness; painful muscles; headache), which are scored on a 5-point 169 
Likert scale (0-32). 170 
Lastly, we hypothesized that self-efficacy is positively associated with better treatment response. 171 
Self-efficacy refers to the belief in one’s competence to cope with a broad range of stressful or 172 
7 
 
challenging demands and the perceived ability to produce a desired action [37]. Above-average levels 173 
of self-efficacy are protective for the onset of depressive disorders [38] and may be related to a 174 
lower risk of relapse or recurrence of depressive disorders [24]. Self-efficacy was measured with the 175 
General Self-Efficacy Scale (GSES) [39] at baseline. The ten items are scored on a 4-point scale, 176 
yielding a total score of 10-40. 177 
Statistical analyses 178 
Clinical moderators 179 
We applied logistic regression analyses to identify subgroups with particularly good responses to S-180 
PCT regarding relapse or recurrence, using interaction terms of randomization status and baseline 181 
characteristics, adjusted for residual depressive symptoms at baseline (QIDS-sr). All interaction terms 182 
were tested separately for statistical significance (p < .10, two-tailed). After that, we performed 183 
subgroup analyses (logistic regression analyses) for all statistically significant moderators.  184 
Cost moderators 185 
Moderators of total costs over twelve months follow-up were tested using linear regression analyses, 186 
adjusted for total costs in the three months before baseline. The same set of putative moderators 187 
was evaluated as mentioned above. Again, we conducted subgroup analyses for the statistically 188 
significant moderators (p < .10, two-tailed) identified in the moderation analyses. In these subgroup 189 
analyses, we dichotomized the continuous variables based on clinical cut-offs (QIDS-sr, 4DSQ) or 190 
median split (age, age of onset, self-efficacy). 191 
Cost-effectiveness analyses 192 
Lastly, we performed cost-effectiveness analyses, stratified for subgroups of the statistically 193 
significant clinical and cost moderators. To create subgroups, we dichotomized continuous variables 194 
based on clinical cut-offs or median split. Cost-effectiveness acceptability curves (CEAC) show the 195 
probability that S-PCT is cost-effective in comparison with TAU for a range of monetary values society 196 
is willing to pay (WTP) to gain one unit of effect (i.e. to prevent one relapse or recurrence). We 197 
estimated the CEACs by non-parametric bootstrapping with 5000 replications and adjusted for 198 
residual depressive symptoms at baseline (QIDS-sr) and total costs in the three months before 199 
baseline (TiC-P). 200 
Missing data 201 
Complete data for the twelve months observation period were collected from 95/124 participants 202 
(77%) in the S-PCT group and 93/124 participants (75%) in the control group (χ2(1) = 0.088, p = .77). 203 
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We imputed the missing data on costs and outcome using multiple imputations by chained equations 204 
(MICE) [40]. Ten complete datasets were needed to reach a loss of efficiency that was smaller than 205 
5% [41]. We performed the analyses in each of the ten data sets and pooled the results.   206 
All analyses were performed with STATA version 14, based on the intention-to-treat principle (ITT). 207 
4. Results 208 
Baseline characteristics 209 
Baseline characteristics of the study sample are shown in Table 1. Participants experienced mild 210 
levels of residual depressive symptoms at baseline, defined as a QIDS-sr score of less than 11. 211 
Clinical moderators 212 
During the twelve month observation period, 44/124 (35.5%) participants in the S-PCT group 213 
compared to 62/124 (50.0%) participants in the TAU group reported a new relapse of recurrence, 214 
resulting in a risk difference of 14% (95%CI = 2 to 24, t(167.7)=-2.25, p=.025) [13]. In the moderation 215 
analyses (Table 2), no statistically significant moderators of treatment outcome in terms of relapse or 216 
recurrence of a depressive disorder were identified.  217 
Cost moderators 218 
The mean difference in total societal costs over 12 months was €2,114 (95%CI= -112 to 4261), after 219 
adjusting for baseline costs [14]. In moderation analyses, we found that the number of previous 220 
episodes was a moderator of total costs during twelve months follow-up (Table 2). Subgroup 221 
analyses showed that total costs were statistically significantly higher in the S-PCT group compared 222 
to the TAU group (€ 4451 [95%CI = 1083 to 7819], p = .010) for participants with four of more 223 
previous episodes. Total costs were not significantly different in the S-PCT group compared to the 224 
TAU group for participants with two or three previous episodes (€ -85, 95%CI = -3273 to 3103, p = 225 
.958). The other interaction terms were not statistically significant. 226 
Cost-effectiveness analyses stratified for moderators 227 
The cost-effectiveness acceptability curve stratified for the number of previous depressive episodes 228 
is displayed in Figure 1. In the main analysis using the full population, the probability that S-PCT was 229 
cost-effective compared to TAU was 95% at a WTP of 40,000 €/patient with relapse or recurrence 230 
prevented. At a WTP of 40,000€, the probability that S-PCT was cost-effective in comparison with 231 
TAU was 99% for participants with two or three previous depressive episodes and 59% for four or 232 
more episodes.  233 
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Moreover, at a probability of 95% of S-PCT being cost-effective compared to TAU in persons with two 234 
to three depressive episodes, the WTP should be 16000€/patient with relapse or recurrence 235 
prevented. Using the same WTP of 16000€, the probability that S-PCT is cost-effective was 61% in the 236 
full population and 11% in persons with four or more episodes.  237 
As the number of previous episodes moderated costs and cost-effectiveness, we also assessed (post-238 
hoc) the effectiveness of S-PCT on preventing relapse and recurrence in stratified regression analyses 239 
for participants with two to three episodes compared to participants with four or more episodes. In 240 
these additional analyses, we found a statistically significant effect of S-PCT on relapse or recurrence  241 
for participants with two to three episodes (OR = 0.35, 95%CI = 0.15 to 0.83, p = .017) but a 242 
statistically non-significant effect of S-PCT for participants with four or more depressive episodes (OR 243 
= 0.61, 95%CI = 0.29 to 1.29, p = .198).  244 
5. Discussion 245 
Main results 246 
This study aimed to identify subgroups for which a supported self-help intervention for recurrent 247 
depression (S-PCT) is more (cost)effective in preventing relapse and recurrence of depressive 248 
disorders.  We found no moderating effect on relapse or recurrence for any of the potential 249 
moderators and, therefore, no subgroups were identified for which S-PCT was particularly effective. 250 
Besides, we found that participants with four or more previous depressive episodes receiving S-PCT 251 
reported higher total costs during follow-up compared to TAU, whereas this difference was not 252 
statistically significant in participants with less than four episodes. As a result, the cost-effectiveness 253 
acceptability curves (CEAC) indicated that S-PCT is more likely to be cost-effective in preventing 254 
relapse or recurrence in participants with two or three episodes than with four or more episodes.  255 
Interpretation of findings, in the context of the literature 256 
We hypothesized that participants at higher risk of relapse or recurrence, for instance participants 257 
with many previous depressive episodes or a high level of residual symptoms, would benefit the 258 
most from S-PCT. This was not confirmed by the results of the moderation analyses. Although a high 259 
number of previous depressive episodes is one of the most important risk factors of relapse and 260 
recurrence of depressive disorders [23], it did not moderate treatment effect in our study, only costs 261 
during follow-up. In contrast to our study, other studies found that PCT in group therapy format was 262 
particularly effective in preventing relapse or recurrence for persons with four [42] to five [43] or 263 
more previous depressive episodes. For instance, Bockting et al. (2006) found that the number of 264 
previous episodes predicted relapse or recurrence in the TAU group but not in the PCT group, which 265 
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indicates that PCT neutralizes the influence of this important risk factor [43]. An explanation for our 266 
deviant results may be that we studied PCT in a less intensive format, namely supported self-help, 267 
compared to group-based PCT in these other studies. 268 
In our study, we found that participants with four or more previous episodes in the S-PCT group 269 
reported higher total costs during follow-up compared to TAU, while we found no difference 270 
between the S-PCT and TAU groups for participants with two or three previous episodes. The higher 271 
costs in the S-PCT group cannot fully be explained by the costs of the intervention itself. Additional 272 
analyses showed that these higher costs largely stem from costs due to lost productivity.  As a 273 
consequence of the higher costs and smaller effect, S-PCT is less likely to be cost-effective in 274 
preventing relapse or recurrence compared to TAU for participants with four or more depressive 275 
episodes than two to three episodes. This finding did not meet our expectations as we hypothesized 276 
that S-PCT would have a higher probability to be cost-effective as compared to TAU in participants 277 
with a higher risk of relapse or recurrence. To our best knowledge, no other relapse or recurrence 278 
studies have examined moderators of costs or have stratified the cost-effectiveness for different 279 
subgroups. 280 
Strengths and limitations 281 
One of the strengths of this study is that we used data from an RCT to evaluate the (cost) 282 
effectiveness of S-PCT for recurrent depression in comparison with TAU. A second strength is that 283 
participants with recurrent depression were included without restrictions on treatment as usual and 284 
antidepressant use, which has a positive impact on the generalizability of our results. The results 285 
should be interpreted in the light of some limitations. First, the Parade study was primarily designed 286 
and powered to assess the (cost)effectiveness of S-PCT in preventing relapse or recurrence of 287 
depressive disorders and not to conduct moderation analyses. As a result, the power to detect all 288 
relevant moderators may have been insufficient [44]. Second, the number of previous depressive 289 
episodes and age of onset were assessed retrospectively in a self-report questionnaire. A structured 290 
interview to assess the course of psychopathology, such as the Life Chart Interview [45], would 291 
perhaps have been more appropriate. In addition, the number of previous episodes was 292 
dichotomized. These limitations might have contributed to our finding that the number of previous 293 
episodes did not moderate the treatment effect in terms of relapse or recurrence of depressive 294 
disorders. However, in the randomization procedure we stratified for number of depressive episodes 295 
to ensure equal number of participants in these subgroups among treatment groups [44, 46]. Third, 296 
due to the type of intervention, participants and counselors were not blinded. This may have 297 
introduced bias. Fourth, in both the S-PCT and TAU group, there were no restrictions to TAU.  298 
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Although the lack of restrictions may result in better generalizability to the real world, we cannot rule 299 
out that participants in the TAU group received treatment for recurrent depression, comparable to S-300 
PCT. Lastly, previous studies have identified patient characteristics that may be relevant for 301 
treatment response, such as stressful life events, daily hassles, coping style, cortisol levels and 302 
childhood abuse [43, 47]. However, these characteristics were not assessed in our study and we were 303 
not able to include these putative moderators in our analyses. 304 
Implications for practice and future research 305 
Our findings showed no moderation effects for certain groups, in terms of effectiveness in preventing 306 
relapse or recurrence of depressive disorders. S-PCT may thus be offered to various types of patients. 307 
Furthermore, we found that S-PCT is more likely to be cost-effective in preventing relapse or 308 
recurrence compared to TAU for participants with two or three previous depressive episodes than 309 
four or more episodes. This indicates that S-PCT may best be offered to persons with few previous 310 
depressive episodes. 311 
Future studies could investigate which type of psychological intervention is most appropriate for 312 
whom. Various psychological interventions to prevent relapse or recurrence were compared to 313 
treatment as usual and antidepressant medication in a meta-analysis by Biesheuvel-Leliefeld et al. 314 
(2015) [7]. They conclude that cognitive therapy, interpersonal therapy and mindfulness based 315 
cognitive therapy are equally effective in preventing relapse and recurrence compared to TAU. 316 
However, they did not assess the differential effectiveness in subgroups of participants. Also, 317 
additional research could compare the effectiveness of psychological interventions in various 318 
delivery modes (e.g. PCT offered in group sessions versus supported self-help), as well as examining 319 
which delivery mode is most suitable for which persons. For instance, self-help PCT may be more 320 
appropriate for persons with a lower risk of relapse or recurrence (i.e. few previous depressive 321 
episodes), while for high risk groups (i.e. many previous episodes) more intensive interventions may 322 
be required that also focus on restoring role functioning, besides reducing the actual risk of relapse 323 
or recurrence, as depressive disorders affect many aspects of life, even after recovery, and costs due 324 
to productivity losses are especially high in this group.  325 
Conclusion 326 
Our results imply that supported self-help PCT is effective in preventing relapse or recurrence of 327 
depressive disorders in a broad range of persons. However, S-PCT is more likely to be cost-effective 328 
in preventing relapse and recurrence in persons with two or three depressive episodes than with four 329 
or more episodes. 330 
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